Bolton LP’s Accelerate Diagnostics AXDX Stock Holding History

Bolton LP’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-2,500	Closed	-$305K	–	171
2013 Q4	$305K	Buy	+2,500	New	+$334K	0.06%	121

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

JMPWA

JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

WIC

Wood Investment Counsel Denver, Colorado $669M AUM 20.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bolton LP's AXDX Position: Q1 2014 in Review

Bolton LP sold out of Accelerate Diagnostics (AXDX) in Q1 2014, closing a stake of 2,500 shares — an estimated $305K sold.

Bolton LP first reported a position in AXDX in Q4 2013 and held it in 1 quarter. The position peaked at $305K in Q4 2013. 56 funds tracked by Wall St. Rank hold AXDX as of Q1 2014.

Bolton LP reported no remaining Accelerate Diagnostics position as of Q1 2014 after selling out during the quarter.
Bolton LP sold 2,500 Accelerate Diagnostics shares in Q1 2014, an estimated $305K.
Bolton LP first reported a position in Accelerate Diagnostics in Q4 2013 and held it in 1 quarter.
Bolton LP's Accelerate Diagnostics position peaked at $305K in Q4 2013.
56 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2014.

Based on Bolton LP's 13F filing for Q1 2014, filed 15 May 2014.